These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 34133478)

  • 61. Burden of liver diseases in the world.
    Asrani SK; Devarbhavi H; Eaton J; Kamath PS
    J Hepatol; 2019 Jan; 70(1):151-171. PubMed ID: 30266282
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Apoptosis and necroptosis in the liver: a matter of life and death.
    Schwabe RF; Luedde T
    Nat Rev Gastroenterol Hepatol; 2018 Dec; 15(12):738-752. PubMed ID: 30250076
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Emricasan (IDN-6556) Lowers Portal Pressure in Patients With Compensated Cirrhosis and Severe Portal Hypertension.
    Garcia-Tsao G; Fuchs M; Shiffman M; Borg BB; Pyrsopoulos N; Shetty K; Gallegos-Orozco JF; Reddy KR; Feyssa E; Chan JL; Yamashita M; Robinson JM; Spada AP; Hagerty DT; Bosch J
    Hepatology; 2019 Feb; 69(2):717-728. PubMed ID: 30063802
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Emricasan Improves Liver Function in Patients With Cirrhosis and High Model for End-Stage Liver Disease Scores Compared With Placebo.
    Frenette CT; Morelli G; Shiffman ML; Frederick RT; Rubin RA; Fallon MB; Cheng JT; Cave M; Khaderi SA; Massoud O; Pyrsopoulos N; Park JS; Robinson JM; Yamashita M; Spada AP; Chan JL; Hagerty DT
    Clin Gastroenterol Hepatol; 2019 Mar; 17(4):774-783.e4. PubMed ID: 29913280
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Liver diseases: A major, neglected global public health problem requiring urgent actions and large-scale screening.
    Marcellin P; Kutala BK
    Liver Int; 2018 Feb; 38 Suppl 1():2-6. PubMed ID: 29427496
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Clinical states of cirrhosis and competing risks.
    D'Amico G; Morabito A; D'Amico M; Pasta L; Malizia G; Rebora P; Valsecchi MG
    J Hepatol; 2018 Mar; 68(3):563-576. PubMed ID: 29111320
    [TBL] [Abstract][Full Text] [Related]  

  • 67. New concepts on the clinical course and stratification of compensated and decompensated cirrhosis.
    D'Amico G; Morabito A; D'Amico M; Pasta L; Malizia G; Rebora P; Valsecchi MG
    Hepatol Int; 2018 Feb; 12(Suppl 1):34-43. PubMed ID: 28681347
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Manual search approaches used by systematic reviewers in dermatology.
    Vassar M; Atakpo P; Kash MJ
    J Med Libr Assoc; 2016 Oct; 104(4):302-304. PubMed ID: 27822152
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Hepatocellular carcinoma.
    Llovet JM; Zucman-Rossi J; Pikarsky E; Sangro B; Schwartz M; Sherman M; Gores G
    Nat Rev Dis Primers; 2016 Apr; 2():16018. PubMed ID: 27158749
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Caspases Connect Cell-Death Signaling to Organismal Homeostasis.
    Galluzzi L; López-Soto A; Kumar S; Kroemer G
    Immunity; 2016 Feb; 44(2):221-31. PubMed ID: 26885855
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Targeting Cell Death and Sterile Inflammation Loop for the Treatment of Nonalcoholic Steatohepatitis.
    Wree A; Mehal WZ; Feldstein AE
    Semin Liver Dis; 2016 Feb; 36(1):27-36. PubMed ID: 26870930
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Exosome Adherence and Internalization by Hepatic Stellate Cells Triggers Sphingosine 1-Phosphate-dependent Migration.
    Wang R; Ding Q; Yaqoob U; de Assuncao TM; Verma VK; Hirsova P; Cao S; Mukhopadhyay D; Huebert RC; Shah VH
    J Biol Chem; 2015 Dec; 290(52):30684-96. PubMed ID: 26534962
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Proteolytic Processing of Interleukin-1 Family Cytokines: Variations on a Common Theme.
    Afonina IS; Müller C; Martin SJ; Beyaert R
    Immunity; 2015 Jun; 42(6):991-1004. PubMed ID: 26084020
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Pathogenesis of liver cirrhosis.
    Zhou WC; Zhang QB; Qiao L
    World J Gastroenterol; 2014 Jun; 20(23):7312-24. PubMed ID: 24966602
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: An update.
    Elpek GÖ
    World J Gastroenterol; 2014 Jun; 20(23):7260-76. PubMed ID: 24966597
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Caspase 3 inactivation protects against hepatic cell death and ameliorates fibrogenesis in a diet-induced NASH model.
    Thapaliya S; Wree A; Povero D; Inzaugarat ME; Berk M; Dixon L; Papouchado BG; Feldstein AE
    Dig Dis Sci; 2014 Jun; 59(6):1197-206. PubMed ID: 24795036
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis.
    Barreyro FJ; Holod S; Finocchietto PV; Camino AM; Aquino JB; Avagnina A; Carreras MC; Poderoso JJ; Gores GJ
    Liver Int; 2015 Mar; 35(3):953-66. PubMed ID: 24750664
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Which is more generalizable, powerful and interpretable in meta-analyses, mean difference or standardized mean difference?
    Takeshima N; Sozu T; Tajika A; Ogawa Y; Hayasaka Y; Furukawa TA
    BMC Med Res Methodol; 2014 Feb; 14():30. PubMed ID: 24559167
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The emerging roles of microvesicles in liver diseases.
    Lemoinne S; Thabut D; Housset C; Moreau R; Valla D; Boulanger CM; Rautou PE
    Nat Rev Gastroenterol Hepatol; 2014 Jun; 11(6):350-61. PubMed ID: 24492276
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Caspase-cleaved fragments of cytokeratin-18 as a marker of inflammatory activity in chronic hepatitis B virus infection.
    Bae CB; Kim SS; Ahn SJ; Cho HJ; Kim SR; Park SY; Song GW; Kim DJ; Hwang SG; Yang JM; Kim YB; Park YN; Shin SJ; Cho SW; Cheong JY
    J Clin Virol; 2013 Dec; 58(4):641-6. PubMed ID: 24210327
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.